A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

It is therefore important to investigate the characteristics of new insulins in this population.

Why It Was Studied

Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with faster absorption.

Who Took Part

According to the abstract, 37 adults were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

The adults were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Neither the adults nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the adults took both Insulin Aspart and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Aging, Blood Glucose, Diabetes Mellitus, Type 1, Glucose Clamp Technique, Hypoglycemic Agents, Insulin Aspart and Insulin, Short-Acting.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 37 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Drugs & aging), a journal based in New Zealand.

More context: the Insulin Aspart compound page.